Gilead Plans Viread Filing For Hepatitis B By Year End
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III data shows significant improvement in viral load in HBV patients treated with Viread versus Hepsera.
You may also be interested in...
Gilead Gets Positive Recommendation From EU Committee To Market Viread For Hepatitis B
Company also awaits August PDUFA date for the same indication in the United States.
Gilead Gets Positive Recommendation From EU Committee To Market Viread For Hepatitis B
Company also awaits August PDUFA date for the same indication in the United States.
Gilead Files Viread sNDA For Chronic Hepatitis B
New marketing application for the HIV therapy went to FDA Oct. 10, firm tells “The Pink Sheet” DAILY.